Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 13/20 | 0.38 |
| ▸ | TACR2 | P21452 | 6/20 | 0.33 |
| ▸ | TACR3 | P29371 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | TAC3 | Q9UHF0 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968840 | 0.90 | TACR1 (0.42) | TACR1TACR2TACR3TAC3 | |
| SCHEMBL15397565 | 0.80 | TACR1 (0.46) | TACR1TACR2TACR3TAC3 | |
| SCHEMBL15397566 | 0.80 | TACR1 (0.46) | TACR1TACR2TACR3TAC3 | |
| SCHEMBL1971048 | 0.78 | TACR1 (0.48) | TACR1TACR2TACR3TAC3 | |
| SCHEMBL30693196 | 0.75 | TACR1 (0.43) | TACR1TACR2TACR3TAC3 | |
| SCHEMBL1969075 | 0.74 | TACR1 (0.48) | TACR1TACR2TACR3KCNH2PDK2 | |
| SCHEMBL1974019 | 0.74 | TACR1 (0.47) | TACR1TACR2TACR3 | |
| SCHEMBL1969497 | 0.74 | TACR1 (0.35) | TACR1FFAR4KCNH2 | |
| Hydrochloric Acid SCHEMBL30693190 | 0.74 | TACR1 (0.45) | TACR1TACR2TACR3OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL1974344 | 0.74 | TACR1 (0.45) | TACR1TACR2TACR3OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | TACR1 13/4885TACR2 29/4885TACR3 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.